Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.
Hosted on MSN2mon
FDA Adds Guillain-Barre Syndrome Warning to Two RSV VaccinesThe FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).
MyChesCo on MSN4mon
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV SeasonsPHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback